← Back to Search

Behavioral Intervention

MedStar Health System for Smoking Cessation (TEAL Trial)

Phase 3

Recruiting

Research Sponsored by Georgetown University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3-month and 6-month assessments

Awards & highlights

TEAL Trial Summary

This trial aims to compare two methods for helping people quit smoking while undergoing lung cancer screening. The main goals are to see how many people quit smoking after 3 months and 6 months, and to

Who is the study for?

The TEAL study is for current smokers aged 50-80 who have smoked more than a pack of cigarettes per year for over 20 years and are eligible for lung screening. Participants must speak English and be able to consent. Those with past lung cancer, hearing or cognitive impairments, or living with someone enrolled can't join.Check my eligibility

What is being tested?

This trial compares two smoking cessation methods: phone-based tobacco treatment combined with nicotine replacement and stepped care intervention versus an e-referral to the Tobacco Quitline. Success is measured by quitting smoking at 3 months (self-reported) and at 6 months (self-reported and confirmed).See study design

What are the potential side effects?

Possible side effects from nicotine replacement may include skin irritation from patches, sleep problems if used close to bedtime, headache, nausea, dizziness, racing heartbeat or nervousness.

TEAL Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3-month and 6-month assessments

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3-month and 6-month assessments

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-month and 6-month assessments for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Biochemically verified smoking abstinence- MHS vs. QL-E arms

Biochemically verified smoking abstinence--continued MHS arm vs Stepped Care

Secondary outcome measures

Costs per arm from the health system perspective

Patient reach and patient engagement

cigarettes per day

+2 more

TEAL Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: MedStar Health SystemExperimental Treatment1 Intervention

Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention

Group II: E-Referral to the Tobacco QuitlineActive Control1 Intervention

Standard tobacco quitline protocol, including coaching, nicotine replacement, and web-, and text-based resources.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Georgetown UniversityLead Sponsor

343 Previous Clinical Trials

135,314 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are prospective patients still eligible to participate in this ongoing medical study?

"Affirmative. The details on clinicaltrials.gov suggest that this investigation is actively seeking individuals to participate. Originally shared on February 22, 2024 and last modified on February 26, 2024, the trial aims to enroll a total of 1188 patients at one location."

Answered by AI

What is the current number of individuals being recruited for participation in this medical research study?

"Indeed, information from clinicaltrials.gov confirms that recruitment is ongoing for this trial. The study was initially posted on February 22nd, 2024 and recently updated on February 26th, 2024. The aim is to enroll a total of 1188 participants at one designated site."

Answered by AI

What are the safety considerations for individuals seeking care at MedStar Health System?

"Our evaluation at Power rates the safety of MedStar Health System as 3, corresponding to a Phase 3 trial status. This indicates existing efficacy data and robust safety data from multiple assessments."

Answered by AI